Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%

11/04/2020 | 09:46pm EDT
FILE PHOTO: A sign marks a Biogen facility in Cambridge

(Reuters) - Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.

An FDA approval could come by March, which would make the drug, aducanumab, the first new treatment for the disease in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition that affects millions of people.

Shares of Biogen and its partner Eisai Co Ltd both jumped 40%. The FDA staff comments also buoyed shares of other Alzheimer's drug developers, including a 15% rise in shares of Eli Lily and Co.

The agency's documents were released ahead of a meeting on Friday of outside experts who will review, and decide whether to recommend approval of, aducanumab, an antibody designed to remove amyloid plaques from the brain.

"Briefing documents suggests a positive Advisory Committee vote, which bodes well for approval," Guggenheim analyst Yatin Suneja said in a research note. Mizuho Securities analyst Salim Syed called it "almost a best-case scenario" for Biogen.

FDA drug reviewers said results from one pivotal trial of aducanumab were persuasive and strongly positive. They acknowledged that a second large trial did not succeed, but maintained it did not detract from the findings of the positive study. The FDA is not obligated to abide by its expert panel recommendations, but typically does.

One statistical reviewer at the FDA said another study is needed to confirm whether aducanumab is effective. "There is no compelling substantial evidence of treatment effect or disease slowing," FDA staffer Tristan Massie wrote in the review.

Alzheimer's disease afflicts nearly 6 million Americans and millions more worldwide. Biogen estimates about 1.5 million people with early Alzheimer's in the United States could be candidates for its drug.

Patient advocacy groups have argued that aducanumab needs to be approved due to that large unmet medical need.

"If a third trial is recommended then years could go by ... while people aren't granted access to the drug," said Dr. Howard Fillit, chief science officer at the Alzheimer's Drug Discovery Foundation.

Biogen and its investors also need an aducanumab approval after the company recently lost a patent fight over its big-selling multiple sclerosis drug Tecfidera. If approved, annual sales are forecast to reach $5.3 billion by 2025, according to Refinitiv.


(For an interactive on Biogen product sales, click herehttps://tmsnrt.rs/2JAaUx0.

Cambridge, Massachusetts-based Biogen in October last year revived its plans to seek approval for aducanumab, months after it had said that an independent futility analysis of its two pivotal studies showed they were unlikely to succeed.

Biogen said it changed course after a new analysis showed a high dose of the drug could slow disease progression.

The FDA staff said data from one of the trials "provides the primary evidence of effectiveness as a robust and exceptionally persuasive study demonstrating" a clinically meaningful treatment effect.

Shares of Biogen were up $99.57 at $346.58, and shares of Eisai were up $30.82 at $110.12.

(Additional reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)

By Deena Beasley and Manojna Maddipatla


ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.75% 297.9658 Delayed Quote.22.60%
EISAI CO., LTD. 1.28% 8450 End-of-day quote.14.62%
LILY GROUP CO., LTD. 3.72% 18.66 End-of-day quote.27.03%
All news about EISAI CO., LTD.
09/15EISAI : To join the global emvironmental initiative 're100'
AQ
09/14EISAI : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Servic..
AQ
09/14EISAI : to Join The Global Environmental Initiative "RE100"
AQ
09/14EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”
PU
09/13EISAI : To present abstracts on oncology products and pipeline at esmo virtual c..
PU
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Servic..
AQ
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch “Humira« Support Tool Ordering..
PU
09/10Japan's Nikkei 225 Up 1.3% on Outlook for Expanded Government Stimulus
MT
09/10Japan's Topix hits highest since 1990 on hopes of new govt, better earnings
RE
09/09Japan shares rally on, Topix hits over 30-year high on earnings optimism
RE
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 694 B 6 340 M 6 340 M
Net income 2022 56 180 M 513 M 513 M
Net cash 2022 155 B 1 417 M 1 417 M
P/E ratio 2022 43,1x
Yield 2022 1,91%
Capitalization 2 422 B 22 128 M 22 127 M
EV / Sales 2022 3,27x
EV / Sales 2023 3,08x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 450,00 JPY
Average target price 12 289,23 JPY
Spread / Average Target 45,4%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.14.62%22 045
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604